Clinical trials: ifosfamide, completed
Diffuse Large B-cell Lymphoma
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose…
- Trial name
- NCT02329080
- Testing
- Methotrexate, Rituximab, Cytarabine
- Where
- 36 sites in Czechia, Italy and 2 more
- Volunteers
- 79 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Refractory Neuroblastoma, Soft Tissue Cancer
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft…
- Trial name
- NICE (NCT06438614)
- Testing
- HITS, Naxitamab + GM-CSF cycles, NICE
- Where
- Spain
- Volunteers
- 47 people
- Sponsor
- Fundació Sant Joan de Déu
Lymphoma
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00345865
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 473 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Sarcoma
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
The primary objective of the study is to compare the progression-free survival (PFS) in the 2 treatment arms The secondary objectives of the study are : To compare the overall survival in the 2 treatment arms To compare the…
- Trial name
- NCT00699517
- Testing
- OMBRABULIN (AVE8062)
- Where
- 45 sites in United States, Belgium and 8 more
- Volunteers
- 355 people
- Sponsor
- Sanofi
Germ Cell Tumor
First Line TIP in Poor Prognosis TGCTs.
TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until progression, unacceptable toxicity, complete response…
- Trial name
- TIP (NCT02414685)
- Testing
- Paclitaxel, Ifosfamide, Cisplatin
- Where
- Slovakia
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute, Slovakia
Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors.
- Trial name
- NCT00618813
- Testing
- radiation therapy, therapeutic conventional surgery, etoposide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Breast Cancer
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006260
- Testing
- cisplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Large-Cell, Diffuse
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated…
- Trial name
- NCT00137995
- Testing
- Rituximab, Etoposide, Carboplatine
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 481 people
- Sponsor
- Lymphoma Study Association
Lymphoma
A Phase II Study of Nasal NK/T-cell Lymphoma
To determine whether adding combinational chemotherapy concurrently to conventional radiation will improve the response rate, event-free survival, and overall survival.
- Trial name
- NCT00292695
- Testing
- VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT
- Where
- Taiwan
- Volunteers
- 33 people
- Sponsor
- National Health Research Institutes, Taiwan
Leukemia
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AIEOP LLA 2000 (NCT00613457)
- Testing
- dexamethasone, asparaginase, cyclophosphamide
- Volunteers
- 2,039 people
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
Leukemia
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002865
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
- Trial name
- NCT03283696
- Testing
- Olaratumab, Doxorubicin, Ifosfamide
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Kidney Cancer, Sarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT00002466
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Testicular Cancer
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors.
- Trial name
- NCT00936936
- Testing
- Gemcitabine, Docetaxel, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00012051
- Testing
- filgrastim, rituximab, carmustine
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 340 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Soft Tissue Sarcoma
Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma
Neo- and adjuvant chemotherapy is used in high-risk soft tissue sarcoma to improve systemic control. Patients in this trial are treated with 4 cycles of chemotherapy (EIA, etoposide, ifosfamide, adriamycin) preoperatively…
- Trial name
- NeoWTS (NCT01382030)
- Testing
- EIA chemotherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00423852
- Testing
- filgrastim, carboplatin, ifosfamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ewing's Family Tumors, Renal Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS…
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma
- Trial name
- NCT01505569
- Testing
- Ifosfamide, Etoposide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Aggressive Non-Hodgkin Lymphoma
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.
- Trial name
- NCT03458260
- Testing
- Pixantrone, Ifosfamide, Etoposide
- Where
- 22 sites in Belgium, France
- Volunteers
- 74 people
- Sponsor
- The Lymphoma Academic Research Organisation
Osteosarcoma
ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities
Post-authorization, observational, multicenter and prospective study in patients between 2 and 30 years old diagnosed with non-metastatic high-grade osteosarcoma of the extremities.
- Trial name
- NCT04383288
- Where
- 17 sites in Spain
- Volunteers
- 115 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas